• Recruiting

AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM

BelaCarD Study

AMaRC: (PHASE I/II)

BELACARD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA

BelaCarD Study

A phase I/II single arm study on the efficacy of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma


AMaRC 19-02 - STUDY TITLE: A phase I/II single arm study of combination belantamab mafodotin, carfilzomib and dexamethasone in patients with early relapsed multiple myeloma (BelaCarD)


Australasian Myeloma Research Consortium


TIME FRAME

2020 – 2024

 

Trial registered on ANZCTR: Registration number - ACTRN12620000490976


BelaCarD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (PHASE I/II) | AMaRC (amarconline.org)

A phase I/II single arm study on the efficacy of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma


https://www.amarconline.org/clinical-trials/belacard


Click here for details

 

Location

Australia

 

#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California

Click here for details

Posts Archive